Nectar Lifesciences Ltd. (IN:NECLIFE)
:NECLIFE
NECLIFE Stock Chart & Stats
₹18.25
-₹0.79(-2.00%)
At close: 4:00 PM EST
₹18.25
-₹0.79(-2.00%)
Day’s Range― - ―
52-Week Range₹9.20 - ₹28.27
Previous CloseN/A
Volume216.67K
Average Volume (3M)34.32K
Market Cap
₹2.65B
Enterprise Value₹7.16B
Total Cash (Recent Filing)₹139.72M
Total Debt (Recent Filing)₹4.59B
Price to Earnings (P/E)7.6
Beta1.13
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding224,260,970
10 Day Avg. Volume25,321
30 Day Avg. Volume34,323
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.56
Price to Sales (P/S)0.32
P/FCF Ratio4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Manufacturing StreamsNectar operates across APIs, finished dosage forms and contract manufacturing, giving multiple durable revenue channels. This structural diversity supports capacity utilization, reduces reliance on a single end-market and helps capture value across the pharma supply chain over months to years.
Stable Capital StructureA moderate debt-to-equity profile and stable equity ratio provide financial flexibility, lowering refinancing risk and preserving capacity for capex or remediation. Over the medium term this supports continuity of manufacturing operations and strategic investments.
Improving Operating Cash FlowRecent improvement in operating cash generation signals better conversion of earnings to cash, strengthening liquidity and ability to fund working capital, capex or debt service internally. Sustained cashflow improvement would materially reduce reliance on external financing.
Bears Say
Severe Revenue DeclineA >50% year-on-year revenue contraction is a structural red flag: it compresses scale economics, raises per-unit fixed costs and limits reinvestment capacity. Persistent top-line decline undermines long-term margin recovery and makes consistent profit restoration harder.
Negative And Declining MarginsDeclining gross margins and a negative net margin indicate pressure on pricing or rising input costs and weak pricing power. Over months this erodes free cash flow potential, constrains R&D/manufacturing upgrades and weakens competitiveness in generics and contract manufacturing.
Extreme EPS VolatilityAn extreme EPS deterioration signals either large one-off losses or structural profitability breakdown. Such volatility damages shareholder returns, limits management flexibility on capital allocation, and raises the risk of further balance-sheet or operational corrective actions.
Nectar Lifesciences Ltd. News
NECLIFE FAQ
What was Nectar Lifesciences Ltd.’s price range in the past 12 months?
Nectar Lifesciences Ltd. lowest stock price was ₹9.20 and its highest was ₹28.27 in the past 12 months.
What is Nectar Lifesciences Ltd.’s market cap?
Nectar Lifesciences Ltd.’s market cap is ₹2.65B.
When is Nectar Lifesciences Ltd.’s upcoming earnings report date?
Nectar Lifesciences Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 51 days.
How were Nectar Lifesciences Ltd.’s earnings last quarter?
Nectar Lifesciences Ltd. released its earnings results on Jan 23, 2026. The company reported ₹0.636 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.636.
Is Nectar Lifesciences Ltd. overvalued?
According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued.
Does Nectar Lifesciences Ltd. pay dividends?
Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of N/A. See more information on Nectar Lifesciences Ltd. dividends here
What is Nectar Lifesciences Ltd.’s EPS estimate?
Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nectar Lifesciences Ltd. have?
Nectar Lifesciences Ltd. has 224,260,970 shares outstanding.
What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?
Nectar Lifesciences Ltd. reported an EPS of ₹0.636 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in IN:NECLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nectar Lifesciences Ltd.
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Medicamen Biotech Limited
―
Sakar Healthcare Ltd
―
Venus Remedies Limited
―
Zim Laboratories Ltd.
―